Cagrilintide

Human evidence can mean a controlled clinical study, an observational study, a safety or exposure report, or evidence from a particular finished formulation. Those are different kinds of information.

Human evidence in specific contexts. Human studies are available in defined contexts, but the evidence remains product-, population-, route-, or outcome-specific.

Preclinical means research in cells, tissues, or animals rather than in people. It can help researchers form a hypothesis, but it cannot establish a human benefit or a complete human safety profile.

Preclinical amylin-receptor pharmacology supported development. Laboratory or animal findings do not establish individual benefit or safety in people.[1]

Preclinical findings do not establish outcomes in people.

Risk information may describe the compound, a finished product, a route, a population, or product-quality concerns. The cited material does not replace a current product label or an individual professional assessment.

This section is about the United States only. Status applies to a product, formulation, route, population, and use—not to a name in the abstract. A status shown here is not a recommendation or a statement about another country.

• Source/status dateJul 22, 2026

  Investigational

  Cagrilintide remains an investigational drug studied in registered clinical trials. This profile does not identify an FDA-approved cagrilintide product.

  Specific product form or route is not separately published in this status record.

  Open source context

The date above is the date attached to the published status record or source context. It is not necessarily the original approval date.

These prompts help organise a conversation with a qualified professional. They do not create a treatment recommendation, dose, or protocol.

• EvidenceWhich human evidence applies to the exact product, form, route, and use being discussed?
• What remains uncertainWhat is known, and what remains uncertain for this specific context?
• RisksWhich important warnings, common effects, and product-quality concerns should be discussed?
• U.S. statusWhat does the U.S. status cover, and what does it not cover?

Related means that the profiles share a topic, pathway, product context, or research question. It does not mean that they are equivalent.

• PramlintideBoth are amylin-pathway compounds with different regulatory status.
• SemaglutideCagrilintide has been studied with semaglutide but remains investigational.

PeptideGrid review date: Jul 22, 2026. Sources support the specific sections that cite them. Publication does not imply endorsement, equivalence, or individual suitability.

1. 1

   Cagrilintide phase 2 weight-management trial

   Lau DCW, et al. Once-weekly cagrilintide for weight management in people with overweight and obesity: a phase 2 trial. The Lancet. 2021.

   The Lancet · Published Nov 16, 2021 · Accessed Jul 22, 2026 · Clinical study

   Open source
2. 2

   Cagrilintide clinical trial record

   ClinicalTrials.gov. NCT03856047: Investigation of efficacy and safety of cagrilintide in people with overweight or obesity.

   U.S. National Library of Medicine · Published Nov 16, 2021 · Accessed Jul 22, 2026 · Reference source

   Open source